Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients

Dennis A. Hesselink*, Daphne M. Hullegie-Peelen, Lukas K. van Vugt

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)567-570
Number of pages4
Issue number10
Early online date28 Jun 2022
Publication statusPublished - Jul 2022

Bibliographical note

Financial & competing interests disclosure
DA Hesselink has received lecture fees and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, Sangamo Therapeutics and Vifor Pharma. He has received grant support from Astellas Pharma, Bristol-Myers Squibb and Chiesi Pharma (paid to the institution). DA Hesselink does not have employment or stock ownership at any of these companies and neither does he have patents or patent applications. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.

Cite this